Comorbidity burden on receipt of adjuvant immunotherapy and survival in patients with stage III melanoma: an analysis of the National Cancer Database
Source: MDLinx, July 2020
Researchers used the National Cancer Database to explore the connection between comorbidity burden, receipt of adjuvant immunotherapy, and survival in patients with stage III melanoma. Sixteen thousand nine hundred six patients with stage III melanoma who had primary site surgery were identified. Lower receipt of adjuvant immunotherapy was associated with greater comorbidity burden, but adjuvant immunotherapy offered comparable survival benefits for patients, regardless of their comorbidity burden.
